ANJULI JINDAL: Open Payments
NPI 1043493372 · ALEXANDRIA, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$904 in 35 payments from 9 companies in 2025. Trend: 2023 $158 · 2024 $503 · 2025 $904
Food & beverage: $904
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 9 | $295 |
| Otsuka America Pharmaceutical, Inc. | 10 | $271 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $89 |
| Alkermes, Inc. | 4 | $79 |
| E.R. Squibb & Sons, L.L.C. | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| ABBVIE INC. | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
Products named: INGREZZA, ABILIFY MAINTENA, CAPLYTA, ABILIFY ASIMTUFII, ARISTADA, REXULTI, COBENFY, UZEDY.
Industry payments across VA — which companies pay providers there.
